anti hiv agents

Summary

Summary: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Top Publications

  1. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
  2. pmc Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 94:13193-7. 1997
  3. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
  4. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
  5. pmc Human immunodeficiency virus reverse transcriptase and protease sequence database
    Soo Yon Rhee
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Nucleic Acids Res 31:298-303. 2003
  6. pmc Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
    Jeffrey A Johnson
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Med 5:e158. 2008
  7. ncbi Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis
    Suzanna Attia
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    AIDS 23:1397-404. 2009
  8. pmc Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
  9. ncbi Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    JAMA 296:679-90. 2006
  10. ncbi Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
    B Autran
    Laboratoire d Immunologie Cellulaire, URA CNRS 625, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris, France
    Science 277:112-6. 1997

Detail Information

Publications342 found, 100 shown here

  1. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  2. pmc Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 94:13193-7. 1997
    ..In addition, the presence of unintegrated HIV-1 DNA in infected resting CD4+ T cells from patients receiving HAART, even those with undetectable plasma viremia, suggests persistent active virus replication in vivo...
  3. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  4. ncbi Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    JAMA 292:191-201. 2004
    ..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
  5. pmc Human immunodeficiency virus reverse transcriptase and protease sequence database
    Soo Yon Rhee
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Nucleic Acids Res 31:298-303. 2003
    ..Sequence data on two new molecular targets of HIV drug therapy--gp41 (cell fusion) and integrase--will be added to the database in 2003...
  6. pmc Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
    Jeffrey A Johnson
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Med 5:e158. 2008
    ..We used sensitive and simple tests to investigate evidence of transmitted drug resistance in antiretroviral drug-naïve persons and assess the clinical implications of minority drug-resistant variants...
  7. ncbi Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis
    Suzanna Attia
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    AIDS 23:1397-404. 2009
    ..To synthesize the evidence on the risk of HIV transmission through unprotected sexual intercourse according to viral load and treatment with combination antiretroviral therapy (ART)...
  8. pmc Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
  9. ncbi Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    JAMA 296:679-90. 2006
    ..Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa...
  10. ncbi Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
    B Autran
    Laboratoire d Immunologie Cellulaire, URA CNRS 625, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris, France
    Science 277:112-6. 1997
    ..Thus, decreasing the HIV load can reverse HIV-driven activation and CD4(+) T cell defects in advanced HIV-infected patients...
  11. ncbi Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
    D R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, University of California San Francisco, 94110, USA
    AIDS 14:357-66. 2000
    ..To examine the relationship between adherence, viral suppression and antiretroviral resistance in HIV-infected homeless and marginally housed people on protease inhibitor (PI) therapy...
  12. ncbi Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, and the Positive Health Program, San Francisco General Hospital, University of California, San Francisco, CA 94143 1372, USA
    Clin Infect Dis 43:939-41. 2006
    ..Although perfect adherence is an important goal, viral suppression is possible with moderate adherence to potent regimens...
  13. ncbi Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy
    Jean Jacques Parienti
    Department of Infectious Diseases and Virology, Côte de Nacre Hospital, Caen, France
    Clin Infect Dis 38:1311-6. 2004
    ..8-180.3; P<.0001). Patients' previous adherence to therapy and drugs genetic barriers, not only the number of pills or doses involved, should be taken into consideration in the decision to simplify highly active antiretroviral therapy...
  14. ncbi Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, UK
    Lancet 352:1725-30. 1998
    ..We examined the change in these mortality rates of HIV-1-infected patients across Europe during 1994-98, and assessed the extent to which changes can be explained by the use of new therapeutic regimens...
  15. pmc Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy
    J B Dinoso
    Departmentsof Medicine and Pharmacology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 106:9403-8. 2009
    ..Our results suggest that residual viremia is not the product of ongoing, complete cycles of viral replication, but rather of virus output from stable reservoirs of infection...
  16. ncbi Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes
    Birgitte B Simen
    454 Life Sciences, a Roche Company, Branford, Connecticut, USA
    J Infect Dis 199:693-701. 2009
    ..Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important...
  17. ncbi Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes
    Jeffrey S A Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, USA
    JAMA 296:782-93. 2006
    ..The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians...
  18. pmc Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings
    Mathieu Forster
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    Bull World Health Organ 86:939-47. 2008
    ....
  19. pmc Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
    T W Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 95:8869-73. 1998
    ....
  20. pmc When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
    ..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
  21. pmc Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
    Ginger Lehrman
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
    Lancet 366:549-55. 2005
    ..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
  22. ncbi Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission
    Newton I Kumwenda
    Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
    N Engl J Med 359:119-29. 2008
    ..Effective strategies are urgently needed to reduce mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) through breast-feeding in resource-limited settings...
  23. pmc HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir
    Tae Wook Chun
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 115:3250-5. 2005
    ..Such events may allow continual replenishment of the CD4+ T cell reservoir and resetting of the half-life of the latently infected, resting CD4+ T cells despite prolonged periods of aviremia...
  24. ncbi Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
    David Coetzee
    Infectious Disease Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory 7925, South Africa
    AIDS 18:887-95. 2004
    ....
  25. ncbi Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
    F van Leth
    International Antiviral Therapy Evaluation Center, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
    Lancet 363:1253-63. 2004
    ..The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz...
  26. ncbi Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
    ..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
  27. pmc HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
    Robert W Shafer
    Division of Infectious Diseases, Stanford University, Stanford, California, USA
    AIDS 21:215-23. 2007
    ..However, such programs will not produce comparable estimates unless a standardized list of drug-resistance mutations is used to define transmitted resistance...
  28. pmc Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings
    Ume L Abbas
    Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
    PLoS ONE 2:e875. 2007
    ..The potential impact of pre-exposure chemoprophylaxis (PrEP) on heterosexual transmission of HIV-1 infection in resource-limited settings is uncertain...
  29. ncbi Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study
    Marguerite Guiguet
    INSERM U943 and UPMC UMR S 943, Paris, France
    Lancet Oncol 10:1152-9. 2009
    ..We examined the effect of these factors on the risk of specific cancers in patients infected with HIV-1...
  30. pmc HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
    R T Davey
    National Institute of Allergy and Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 96:15109-14. 1999
    ..Virologic relapse occurs rapidly in patients who discontinue suppressive drug therapy, even in patients with a markedly diminished pool of resting, latently infected CD4(+) T cells...
  31. pmc Inflammatory and coagulation biomarkers and mortality in patients with HIV infection
    Lewis H Kuller
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    PLoS Med 5:e203. 2008
    ..We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis...
  32. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  33. ncbi Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
    ..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
  34. ncbi Inhibiting sexual transmission of HIV-1 infection
    Robin J Shattock
    Department of Cellular and Molecular Medicine, Infectious Diseases, St George s Hospital Medical School, London, UK
    Nat Rev Microbiol 1:25-34. 2003
    ....
  35. pmc Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
    Patricia Cane
    BMJ 331:1368. 2005
    ..To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom...
  36. ncbi Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Gerd Fatkenheuer
    Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
    Nat Med 11:1170-2. 2005
    ..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
  37. ncbi Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study
    Ibou Thior
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass 02115, USA
    JAMA 296:794-805. 2006
    ..Postnatal transmission of human immunodeficiency virus-1 (HIV) via breastfeeding reverses gains achieved by perinatal antiretroviral interventions...
  38. pmc Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda
    Steven J Reynolds
    National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    AIDS 23:697-700. 2009
    ..Our objective was to evaluate immunologic failure criteria against gold standard virologic monitoring...
  39. ncbi In vitro and in vivo: the story of nonoxynol 9
    Sharon L Hillier
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Acquir Immune Defic Syndr 39:1-8. 2005
    ..This article presents a review of the in vitro, ex vivo, and animal model data on the safety of N-9 and a critical analysis of their predictive power based on the results of multiple safety and efficacy trials...
  40. ncbi Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
    S G Deeks
    University of California, San Francisco, and San Francisco General Hospital, USA
    N Engl J Med 344:472-80. 2001
    ..In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown...
  41. ncbi The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1
    E Oberlin
    Unite d Immunologie Virale, Institut Pasteur, Paris, France
    Nature 382:833-5. 1996
    ....
  42. ncbi Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients
    Patricia Garcia de Olalla
    Epidemiology Service, Municipal Institute of Public Health of Barcelona, and Autónoma University of Barcelona, Spain
    J Acquir Immune Defic Syndr 30:105-10. 2002
    ..To assess the effect of antiretroviral therapy (ART) adherence on survival in HIV-infected patients...
  43. ncbi Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel
    M S Hirsch
    Harvard Medical School, Boston, MA, USA
    JAMA 279:1984-91. 1998
    ..To review current knowledge of the biology and clinical implications of human immunodeficiency virus (HIV) resistance to antiretroviral drugs, describe assays for measuring resistance, and assess their use in clinical practice...
  44. pmc Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency
    Elias K Halvas
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, S818 Scaife Hall, 3550 Terrace St, Pittsburgh, PA 15261, and Children s Hospital of Los Angeles, CA, USA
    J Clin Microbiol 44:2612-4. 2006
    ..1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy...
  45. ncbi A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors
    Bluma Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 17:F1-5. 2003
    ..This study evaluates the prevalence of V106 (GTG) and 106M (ATG) codons in clinical isolates as well as the effects of V106M on resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI)...
  46. pmc Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
    Graeme Meintjes
    Institute of Infectious Diseases and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa
    Lancet Infect Dis 8:516-23. 2008
    ..It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data...
  47. ncbi Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients
    A d'Arminio Monforte
    Institute of Infectious and Tropical Diseases, University of Milan, Italy
    AIDS 14:499-507. 2000
    ....
  48. ncbi Learning multiple evolutionary pathways from cross-sectional data
    Niko Beerenwinkel
    Max Planck Institut für Informatik, Stuhlsatzenhausweg 85, D 66123 Saarbrucken, Germany
    J Comput Biol 12:584-98. 2005
    ..We obtain a generative probabilistic model for the development of drug resistance in HIV that agrees with biological knowledge. Further applications and extensions of the model are discussed...
  49. pmc Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
    Shawn E Kuhmann
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Virol 78:2790-807. 2004
    ..2-CCR5 cells under conditions where gp120 proteins from the parental virus and a partially AD101-resistant virus bound strongly. Hence, the full impact of the V3 substitutions may only be apparent at the level of the native Env complex...
  50. pmc CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 22:841-8. 2008
    ..Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients...
  51. ncbi Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
    M S Sulkowski
    Department of Medicine, Johns Hopkins University Schools of Medicine, Baltimore, MD 21287, USA
    JAMA 283:74-80. 2000
    ..Use of antiretroviral drugs, including protease inhibitors, for treatment of human immunodeficiency virus (HIV) infection has been anecdotally associated with hepatotoxicity, particularly in persons coinfected with hepatitis C or B virus...
  52. ncbi Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire
    Gaston Djomand
    Projet RETRO CI, Abidjan, Cote d Ivoire
    AIDS 17:S5-15. 2003
    ..This evaluation of the project is the first to provide results of a large number of HIV-infected patients receiving antiretroviral therapy in West Africa...
  53. ncbi Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26
    Hiroyuki Gatanaga
    AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan
    Clin Infect Dis 45:1230-7. 2007
    ..Here, we tested the feasibility of genotype-based dose reduction of EFV...
  54. ncbi Self-Reported adherence to antiretroviral treatment among HIV-infected people in Central China
    Honghong Wang
    School of Nursing, Central South University, Changsha, Hunan, China
    AIDS Patient Care STDS 22:71-80. 2008
    ..Prospective studies are needed to evaluate the efficacy of reminder devices to improve adherence in this population and to describe the prevalence and incidence of ARV resistance...
  55. ncbi Prevalence and predictive value of intermittent viremia with combination hiv therapy
    D V Havlir
    University of California, San Diego, 150 W Washington, Suite 100, San Diego, CA 92103, USA
    JAMA 286:171-9. 2001
    ....
  56. ncbi HIV drug resistance
    Francois Clavel
    Unité de Recherche Antivirale, Institut National de la Sante et de la Recherche Medicale, Unité 552, Hopital Bichat Claude Bernard, Paris
    N Engl J Med 350:1023-35. 2004
  57. ncbi Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients
    Pierre De Beaudrap
    Hospices Civils de Lyon, Service de Biostatistique, Lyon, F 69424, France
    AIDS Res Hum Retroviruses 24:753-60. 2008
    ..Adverse effects were different between NVP and EFV, but long-term tolerance was good for both. This analysis provided further information on long-term tolerance and efficacy of EFV and NVP in a resource-limited setting...
  58. ncbi Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire
    Raoul Moh
    Programme PAC CI, Abidjan, Cote d Ivoire
    Antivir Ther 10:615-24. 2005
    ..We estimated the incidence of haematological disorders during the first 6 months of a zidovudine-containing highly active antiretroviral therapy (HAART) regimen in sub-Saharan African adults receiving cotrimoxazole...
  59. pmc Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase
    P L Boyer
    ABL Basic Research Program, National Cancer Institute Frederick Cancer Research and Development Center, Frederick, Maryland 21702 1201, USA
    J Virol 75:4832-42. 2001
    ..Steric constraints involving the azido group cause the end of an AZT 5'-monophosphate-terminated primer to preferentially reside at the nucleotide binding site, which favors excision...
  60. pmc A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients
    Jianqing J Yu
    Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Virology 379:78-86. 2008
    ..When we applied our integration assay to patient PBMCs, we found that the use of HAART is associated with reduced levels of integrated DNA...
  61. ncbi Antiviral inhibition of the HIV-1 capsid protein
    Chun Tang
    Howard Hughes Medical Institute and Department of Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250 5398, USA
    J Mol Biol 327:1013-20. 2003
    ..These findings lay the groundwork for the development of assembly inhibitors as a new class of therapeutic agents for the treatment of AIDS...
  62. pmc Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity
    Samir Abdurahman
    Division of Clinical Microbiology, Karolinska Institutet, F68 Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    Antimicrob Agents Chemother 52:3737-44. 2008
    ..As an antiviral compound, alpha-HGA has an unusually simple structure, a pronounced antiviral specificity, and a novel mechanism of antiviral action. As such, it might prove to be a lead compound for a new class of anti-HIV substances...
  63. ncbi The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa
    Sydney Rosen
    Center for International Health and Development, Boston University, Boston, MA 02118, USA
    Trop Med Int Health 13:1005-15. 2008
    ..Estimate the average outpatient cost per patient in care and responding to treatment 1 year after initiation of antiretroviral therapy (ART) under different models of treatment delivery in South Africa...
  64. ncbi The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry
    C C Bleul
    The Center for Blood Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 382:829-33. 1996
    ....
  65. ncbi Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists
    Rama Kondru
    Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA
    Mol Pharmacol 73:789-800. 2008
    ..The fully mapped binding pocket of CCR5 is being used for structure-based design and lead optimization of novel anti-HIV CCR5 inhibitors with improved potency and better resistance profile...
  66. ncbi Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study
    Jean Francois Etard
    UMR 145 HIV AIDS and Associated Diseases, Research Institute for Development IRD University of Montpellier, 911 Avenue Agropolis, 34394 Montpellier Cedex 1, France
    AIDS 20:1181-9. 2006
    ..To evaluate survival and investigate causes of death among HIV-1 infected adults receiving HAART in Senegal...
  67. ncbi The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients
    Joel E Gallant
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 22:2155-63. 2008
    ..We analyzed the renal safety of TDF compared with thymidine analogue-containing (control) regimens through 144 weeks from two clinical trials in antiretroviral-naive HIV-infected patients...
  68. ncbi HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization
    Ron Kagan
    Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California 92690, USA
    AIDS Res Hum Retroviruses 20:1-9. 2004
    ..Continued monitoring of ARV resistance prevalence, patterns, and utilization trends in clinical databases provides insight into the evolving relationship between clinical practice and ARV resistance...
  69. pmc The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages
    S Aquaro
    Laboratory of Experimental Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Virol 75:4402-6. 2001
    ..LD78beta strongly downregulated CCR5 expression in M/M, thereby explaining its potent antiviral activity...
  70. ncbi Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study
    Nina Friis-Møller
    DAD Coordinating Centre, Copenhagen HIV Programme, Hvidovre University Hospital, Copenhagen, Denmark
    AIDS 17:1179-93. 2003
    ..To determine the prevalence of risk factors for cardiovascular disease (CVD) among HIV-infected persons, and to investigate any association between such risk factors, stage of HIV disease, and use of antiretroviral therapies...
  71. ncbi The cost effectiveness of combination antiretroviral therapy for HIV disease
    K A Freedberg
    Division of General Internal Medicine and the Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    N Engl J Med 344:824-31. 2001
    ..We estimated the clinical benefits and cost effectiveness of three-drug antiretroviral regimens...
  72. ncbi A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV
    Robert Grossberg
    Division of Infectious Diseases, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    J Clin Epidemiol 57:1107-10. 2004
    ..The goal of this study was to determine the validity and utility of a pharmacy-based time-to-refill measure of antiretroviral therapy adherence...
  73. pmc A cell-penetrating helical peptide as a potential HIV-1 inhibitor
    Hongtao Zhang
    Laboratory of Molecular Modeling and Drug Design, Lindsley F Kimball Research Institute of the New York Blood Center, 310 E 67th Street, New York, NY 10021, USA
    J Mol Biol 378:565-80. 2008
    ..This proof-of-concept cell-penetrating peptide may aid validation of capsid as an anti-HIV-1 drug target and may help in designing peptidomimetics and small molecule drugs targeted to this protein...
  74. ncbi Provider-initiated HIV testing and counselling for TB patients and suspects in Nairobi, Kenya
    J Odhiambo
    United States Centers for Disease Control and Prevention, Nairobi, Kenya
    Int J Tuberc Lung Dis 12:63-8. 2008
    ..Integrated tuberculosis (TB) and human immunodeficiency virus (HIV) services in a resource-constrained setting...
  75. ncbi HIV preferentially infects HIV-specific CD4+ T cells
    Daniel C Douek
    Vaccine Research Center, NIAID, NIH, Maryland 20892, USA
    Nature 417:95-8. 2002
    ..Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption...
  76. ncbi Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa
    Catherine G Sutcliffe
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
    Lancet Infect Dis 8:477-89. 2008
    ....
  77. ncbi Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
    R S Hogg
    Director, AIDS Research Programme, St Paul's Hospital/University of British Columbia, 667-1081 Burrard St, Vancouver, British Columbia V6Z 1Y6, Canada
    JAMA 286:2568-77. 2001
    ..In our study, disease progression to death and AIDS or death was clustered among patients starting therapy with CD4 cell counts less than 200/microL...
  78. ncbi Modelling the effect of combination antiretroviral treatments on HIV incidence
    M G Law
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW 2010, Australia
    AIDS 15:1287-94. 2001
    ....
  79. ncbi Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated
    Jeffrey A Johnson
    Laboratory Branch, National Center for HIV, STD, and Tuberculosis Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 192:16-23. 2005
    ..These findings indicate that resistance mutations emerged in at least 65% of the women after SD-NVP and emphasize the importance of further research to determine the clinical implications...
  80. ncbi Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
    S Staszewski
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Infektionsambulanz, Haus 68, Theodor Stern Kai 7, D 60596 Frankfurt, Germany
    JAMA 285:1155-63. 2001
    ..However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment...
  81. ncbi Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program
    Rob Schuurman
    Department of Virology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
    AIDS Res Hum Retroviruses 18:243-8. 2002
    ..Drug resistance mutations are frequently missed. Therefore, quality control programs are urgently needed. Until these are widely implemented, clinicians must consider this issue and interpret the reported genotyping results with caution...
  82. ncbi Adherence to antiretroviral medication among HIV-positive patients in Thailand
    Wantana Limkulpong Maneesriwongul
    Community Health Nursing Division, Nursing Department, Ramathibodi Faculty of Medicine, Mahidol University, Bangkok, Thailand
    J Acquir Immune Defic Syndr 43:S119-22. 2006
    ..The use of antiretroviral (ARV) medications is expanding rapidly in Thailand. The determinants of optimal adherence for HIV-positive patients in Thailand are unknown...
  83. ncbi Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes
    Catherine Tamalet
    Laboratoire de Virologie, CHRU La Timone, 13005 Marseille, France
    AIDS 17:2383-8. 2003
    ..The aim of this study was to assess the extent of multiple drug resistance among individuals followed for HIV-1 infection in France...
  84. ncbi Adherence to medication regimens among children with human immunodeficiency virus infection
    C Reddington
    Pediatric Spectrum of Disease Project, University of Massachusetts Medical School, Jamaica Plain, USA
    Pediatr Infect Dis J 19:1148-53. 2000
    ..Rigorous adherence to antiretroviral medication regimens is necessary to achieve and maintain undetectable viral levels. This study describes adherence in a population of children with HIV infection...
  85. pmc Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy
    Gregory P Bisson
    Department of Medicine, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS Med 5:e109. 2008
    ....
  86. pmc Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission
    Carey Farquhar
    Department of Medicine, University of Washington, Seattle, WA 98104 249, USA
    J Acquir Immune Defic Syndr 37:1620-6. 2004
    ..004). Partner participation in VCT and couple counseling increased uptake of nevirapine and formula feeding. Antenatal couple counseling may be a useful strategy to promote HIV-1 prevention interventions...
  87. ncbi In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials
    Deborah Tien
    Biosyn, Inc, Huntingdon Valley, PA 19006, USA
    AIDS Res Hum Retroviruses 21:845-53. 2005
    ....
  88. ncbi A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody
    S Jiang
    The Lindsley F Kimball Research Institute, New York Blood Center, NY 10021, USA
    J Virol Methods 80:85-96. 1999
    ....
  89. ncbi Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1
    A K Debnath
    Lindsley F Kimball Research Institute, The New York Blood Center, 310 East 67th Street, New York, New York 10021, USA
    J Med Chem 42:3203-9. 1999
    ..These two compounds will be used as leads to design more effective HIV-1 inhibitors targeted to the HIV-1 gp41 core structure...
  90. pmc Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis
    Sarah Palmer
    HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 43:406-13. 2005
    ..In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis...
  91. ncbi Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients
    Michael D Miller
    Gilead Sciences, Foster City, California 94404, USA
    J Infect Dis 189:837-46. 2004
    ..The results from these controlled clinical trials provide guidance for the use of tenofovir DF for treatment-experienced patients...
  92. ncbi High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda
    Johan van Griensven
    Medecins Sans Frontieres, Kimihurura, Kacyiru, 1361 Kigali, Rwanda
    Trans R Soc Trop Med Hyg 101:793-8. 2007
    ..Lipoatrophy appears to be an important long-term complication of WHO-recommended first-line ART regimens. These data highlight the urgent need for access to more affordable and less toxic ART regimens in resource-limited settings...
  93. ncbi Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens
    K J Roberts
    University of California, Los Angeles, USA
    AIDS Patient Care STDS 14:155-68. 2000
    ..Other barriers, however, such as the complexity of the medications, highlight the need for simplified antiretroviral regimens...
  94. ncbi Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience
    Freddy Perez
    Institut de Santé Publique, d Epidémiologie et de Développement ISPED, Universite Victor Segalen, Bordeaux, France
    Trop Med Int Health 9:774-83. 2004
    ..To report on activities and lessons learned during the first 18 months of a rural programme of prevention of mother-to-child transmission of HIV (PMTCT) in Zimbabwe...
  95. ncbi Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    Jacob P Lalezari
    Quest Clinical Research, Mount Zion Hospital and the University of California, San Francisco, San Francisco 94115, USA
    N Engl J Med 348:2175-85. 2003
    ..The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor...
  96. ncbi Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort
    John L Perez
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 36:212-8. 2003
    ..28 (95% CI, 0.15-0.52) for treated older adults. The effect of HAART substantially improves the survival rate for older individuals and supports the importance of treatment in this group...
  97. pmc Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells
    Jiehua Zhou
    Division of Molecular Biology, Beckman Research Institute of City of Hope, City of Hope, Duarte, CA 91010, USA
    Nucleic Acids Res 37:3094-109. 2009
    ..Our results provide a set of novel inhibitory agents for blocking HIV replication and further validate the use of aptamers for delivery of Dicer substrate siRNAs...
  98. ncbi Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
    Erik De Clercq
    Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
    Int J Antimicrob Agents 33:307-20. 2009
    ..These compounds should be used in drug combination regimens to achieve the highest possible benefit, tolerability and compliance and to diminish the risk of resistance development...
  99. pmc In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA
    Mark Sharkey
    Program in Molecular Medicine, University of Massachusetts, 373 Plantation St, Biotech 2, Suite 319, Worcester, MA 01605, USA
    J Virol 79:5203-10. 2005
    ..Therefore, evolution of episomal viral cDNAs is a valid surrogate of ongoing viral replication in HIV-1-infected individuals...
  100. pmc Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis
    Andrea L Ciaranello
    The Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 49:1915-27. 2009
    ..We sought to derive pooled estimates of the 12-month rate of virologic suppression (HIV RNA, <400 copies/mL) and gain in CD4 cell percentage (DeltaCD4%) for children initiating ART in resource-limited settings...
  101. pmc In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine
    Roger Paredes
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Virol 83:2038-43. 2009
    ..After a lag phase of variable duration, wild-type variants emerged due to continued evolution of pol and back mutation rather than through emergence of an archived wild-type variant...

Research Grants64

  1. The Role of Alcohol in HIV Therapy Hepatotoxicity
    Craig J McClain; Fiscal Year: 2012
    ..Here, we will study hepatotoxicity due to alcohol/HAART interactions to further define disease mechanisms and create therapeutic interventions. ..
  2. Markers of HIV Brain Disease under HAART: Validation in a Mouse Model
    David J Volsky; Fiscal Year: 2012
    ....
  3. Effect of Iron Chelators on HIV-1 transcription
    ZUFAN KEREGO DEBEBE; Fiscal Year: 2011
    ..These findings will provide information in the search for alternative therapeutic approaches that are hopefully more effective and efficient to treat HIV-1. Iron chelators could add to improve the treatment of HIV disease. ..
  4. NOVEL AUREOLIC ACID TYPE ANTITUMOR AGENTS
    JURGEN T ROHR; Fiscal Year: 2013
    ..New resulting MTM analogues will be submitted to the NCI DTP (developmental therapeutics program) for further mechanistic investigations. ..
  5. Enhancing Intestinal &Brain Uptake of Anti-AIDS Drugs
    Patrick J Sinko; Fiscal Year: 2013
    ....
  6. Phosphorylation of CDK9 by CDK2 in HIV-1 replication
    Denitra Breuer; Fiscal Year: 2011
    ..Our findings from this research will provide valuable information regarding the use of CDK2 as a possible target for HIV-1 drug therapy. ..
  7. Anti-HIV Neuroimmunomodulatory Therapy with Neurokinin-1 (NK1-R) Antagonists
    STEVEN DANIEL DOUGLAS; Fiscal Year: 2013
    ..This NK1RA has activity as an antiviral HIV agent that improves innate immunity (Natural Killer cells) and has positive neurobehavioral effects. NK1RA are a potential novel therapy for neuroAIDS...
  8. Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101
    James O Kahn; Fiscal Year: 2010
    ..Specifically the project will examine the medication adherence for antiretroviral medications and common medical and mental health conditions such as depression, hypertension, diabetes and hypercholesterolemia. ..
  9. SYNTHESIS AND BIOTRANSFORMATION OF ANTI-HIV PRODRUGS
    Chung K Chu; Fiscal Year: 2010
    ..If any prodrugs are found to be promising during these studies, we plan to advance them as clinical candidates. ..
  10. Rescuing the anti-HIV activity of APOBEC3G with small-molecule chaperons
    Sergey N Savinov; Fiscal Year: 2010
    ..We propose to develop a novel anti-HIV therapeutic strategy that will rescue the natural antiviral mechanism without the danger of producing drug-resistant viruses. ..
  11. Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
    AWEWURA JACOB KWARA; Fiscal Year: 2013
    ..Without such data, rational decisions about prescribing anti-TB and anti-HIV medications in children are not possible. PHS 398/2590 (Rev. 11/07) Page Continuation Format Page ..
  12. A Novel Anti-HIV Activity of CCR6 via APOBEC3G: Relevance to CNS Infection
    Alfredo Garzino-Demo; Fiscal Year: 2013
    ..These studies are highly relevant to prevention and treatment of HIV infection because they will contribute knowledge that can be used to develop novel anti-HIV drugs that will target CCR6. ..
  13. Alternative Formulations of Tenofovir and UC781
    Lisa C Rohan; Fiscal Year: 2013
    ..Formulation strategies to address solubility and stability issues related with UC781 and alternate film manufacturing techniques will be studied. ..
  14. Novel targets for discovering peptide inhibitors of HIV-1 replication
    Xinhong Dong; Fiscal Year: 2011
    ..Our studies will take important steps toward developing the prototype of a novel class of anti-HIV inhibitors. ..
  15. Discovery of Novel HIV-1 Reverse Transcriptase Inhibitors by Fragment Screening
    ANGELA MCKOY; Fiscal Year: 2013
    ..The fragment screening approach allows for efficient search of chemical space and should lead to the identification of novel scaffolds for inhibiting HIV-1 RNH activity at both the active site and allosteric pockets. ..
  16. Discovery and Optimization of Novel Integrase Inhibitors as Anti-HIV Agents
    John K Buolamwini; Fiscal Year: 2010
    ..The PI has discovered potent integrase inhibitors. The objectives of the grant proposal are to optimize activity and test toxicity. ..
  17. Cellular Efflux and Metabolism of Protease Inhibitors
    Ashim Mitra; Fiscal Year: 2004
    ..The brain parenchymal and alveolar lining - two sanctuary sites that are 'protected' from optimal antiretroviral drug access. 4) to study the effect of protein binding on the influx and efflux of model compounds, and anti-HIV drugs. ..
  18. Structure activity and structure property relationships for novel anti-HIV agents
    KATHLEEN MARY FREY; Fiscal Year: 2013
    ..The combination of both SAR and SPR for leading NNRTI compounds will prioritize future development and provide structural information for rational drug design of efficacious NNRTIs. ..
  19. Targeting HIV Capsid Assembly
    Susana T Valente; Fiscal Year: 2013
    ..Our goal is to provide the scientific community with freely accessible robust assays and potent, diversely acting HIV capsid inhibitors active in nanomolar concentrations. ..
  20. Modified Triterpines as Potent HIV Fusion Inhibitors
    Kuo Hsiung Lee; Fiscal Year: 2012
    ..The aim is to discover an optimal compound that, with the help of a pharmaceutical partner, can be developed as an anti- AIDS clinical trial candidate and, ultimately, as a new drug to treat AIDS-infected patients. ..
  21. Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release
    Paula M Cannon; Fiscal Year: 2010
    ..PHS 398 (Rev. 09/04) Page 2 Principal Investigator/Program Director (Last, first, middle): CANNON, PAULA, M ..
  22. Rational Design of HIV Fusion Inhibitors Targeting gp41
    Shibo Jiang; Fiscal Year: 2010
    ..Therefore, this research is relevant to public health. ..
  23. DNA SYNTHESIS AND RECOMBINATION BY HIV DNA POLYMERASE
    Robert A Bambara; Fiscal Year: 2011
    ..This mechanism can produce viruses with increased or multi-drug resistance. Our results will help us to understand and defeat this mechanism so that anti-AIDS drugs can be more effective. ..
  24. Nucleoside Transporters In HAART Mitochondrial Toxicity
    John Buolamwini; Fiscal Year: 2006
    ..abstract_text> ..
  25. The role of envelope phosphatidylserine in the binding of HIV to target cells
    KOKI MORIZONO; Fiscal Year: 2012
    ..Identification of this novel binding mechanism will lead to new approaches to prevent HIV transmission among people and to inhibit HIV replication in patients. ..
  26. A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancy
    THOMAS MICHAEL ZYDOWSKY; Fiscal Year: 2013
    ....
  27. STRUCTURES AND INTERACTIONS OF CHEMOKINE RECEPTORS
    Ziwei Huang; Fiscal Year: 2010
    ....
  28. High-throughput screening for HIV assembly and maturation inhibitors
    Wuyuan Lu; Fiscal Year: 2013
    ..Our long-term objective is to develop HIV assembly and maturation inhibitors as a novel class of therapeutic agents for the prevention of HIV-1 infection and the treatment of AIDS. ..
  29. Determinates of anti-HIV nucleic acid aptamer potency and resistance
    Donald H Burke; Fiscal Year: 2012
    ....
  30. CNS targeted delivery of anti-HIV drugs
    Rodney J Y Ho; Fiscal Year: 2010
    ..We envisioned that this product will be used to suppress virus in the CNS as an adjunct to the current oral HARRT, which are effective for suppressing HIV in blood. ..
  31. The Biosynthesis of Ladderane Lipids
    Reid McCarty; Fiscal Year: 2013
    ....
  32. POTENT NEW NUCLEOSIDE ANALOGS FOR DRUG RESISTANT HIV
    Karl Y Hostetler; Fiscal Year: 2010
    ..This proposal is to evaluate and develop one of five highly potent new antiviral phosphonates of our design for treatment of drug resistant HIV infection. ..
  33. Expanded Phase II Trial of Carraguard for Prevention of HPV Infection
    Mark H Einstein; Fiscal Year: 2013
    ..Decreasing HPV rates would have a significant impact on reducing persistent HPV infection, abnormal Pap tests, and cervical cancer nationally and worldwide. ..
  34. Bioactivity of Aptamers Targeted to HIV Reverse Transcriptase
    Margaret J Lange; Fiscal Year: 2012
    ..In addition to the potential for therapeutic application, the project will increase understanding of HIV resistance. ..
  35. ANTI-AIDS NUCLEOSIDE CONJUGATES OF ETHER PHOSPHOLIPIDS
    CHUNG HONG; Fiscal Year: 1992
    ..The proposed conjugates and the micelle-solubilized drug formulation will be sent to the National Institute of Allergy and Infectious Diseases for screening of anti-HIV activity...
  36. Development of Novel Nucleoside Triphosphate Prodrugs
    BYRON WILLIS PURSE; Fiscal Year: 2012
    ..The results of these studies will be used to direct the synthesis of prodrugs of 3'- azido-3'-deoxythymidine triphosphate that will be tested as inhibitors of HIV. ..
  37. pH Responsive anti-HIV Nanoparticles
    Rodney J Y Ho; Fiscal Year: 2013
    ..The proposed novel strategies are designed to address this unmet medical need and may eventually lead to a cure for HIV/AIDS. ..
  38. EVALUATION OF THE PHARMACOKINETIC PROFILE, EFFECTS ON THE MECHANISMS
    ERIN ALLEN; Fiscal Year: 2013
    ..Alternatively, non-hormonal contraceptive drugs may provide an opportunity to be able to be combined with anti-HIV drugs and provide dual purpose protection. ..
  39. Synthesis of Novel Water-Soluble Glycodendrimers as Anti-HIV Agents
    KATHERINE MCREYNOLDS; Fiscal Year: 2009
    ..This research seeks to develop a new class of anti-HIV drugs. ..
  40. HIV-1 reverse transcriptase structure: function, inhibition, and resistance
    EDWARD V ARNOLD; Fiscal Year: 2013
    ..The proposed studies will enhance opportunities for targeting known and new sites on RT including RNase H, the only HIV enzyme not yet blocked by anti-AIDS drugs. ..
  41. Computer-Aided Design of Anti-HIV Drugs
    William L Jorgensen; Fiscal Year: 2013
    ..Similar analyses are being carried out for the other prominent clinical variant, Lys103Asn;only a ca. 10-fold gain is needed to bring the potency towards strains with this replacement to the 10-nM level. ..
  42. Targeting HIV infectivity by stimulating cholesterol efflux
    MICHAEL ILYA BUKRINSKY; Fiscal Year: 2010
    ..These agents target HIV infectivity by a mechanism different from that of other anti-HIV drugs, and thus would be a useful addition to a drug combination used for highly active anti-retroviral therapy. ..
  43. Betulinic acid derivatives as anti-HIV agents
    Chin Ho Chen; Fiscal Year: 2013
    ..The proposed study is expected to overcome this drug resistance and, as a result, will have high impact on developing anti-HIV-1 maturation inhibitors for AIDS therapy. ..
  44. CENTRAL NERVOUS SYSTEM STRATEGIES TARGETING THE HIV SANC
    Bradley Anderson; Fiscal Year: 2003
    ..As observed in children, the infant macaques exhibit a higher incidence of neuro-AIDS than adults which can be characterized by delays in neurological development. ..
  45. Efficacy Testing of HIV-Specific Microbicides in Humanized Mice
    Ramesh Akkina; Fiscal Year: 2012
    ..4. Evaluate a combinatorial microbicide strategy using select anti-HIV agents with different modes of action. 5. Evaluate the safety and potential toxicities of promising microbicide candidates in vivo. ..
  46. NEW PHENYL NUCLEOSIDES AS ANTI-HIV AGENTS
    Shashikant Phadtare; Fiscal Year: 2003
    ..abstract_text> ..
  47. BOTANICAL/DRUG INTERACTIONS IN HIV: GLUCURONIDATION
    Philip Smith; Fiscal Year: 2004
    ..Piperine will also be examined in vitro for potential inhibition of oxidative metabolism of anti-HIV drugs such as the protease inhibitors. ..
  48. High-throughput Computational Docking Screen for Small-molecule Inhibitors of HIV
    Simon Cocklin; Fiscal Year: 2011
    ..The compounds identified within this proposal have the potential to serve as templates for novel anti-HIV agents while also providing reagents with which to dissect the basic biology of HIV-1. ..
  49. Discovery of drugs for use in the treatment and prevention of HIV infection using
    DUANE contact RUFFNER; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: We will use innovative new technology to develop optimized anti-HIV agents with a variety of mechanisms. These agents will be leads for clinical development. ..
  50. Interaction between HIV-1 Vif and a Host Key Immune Regulator Component
    SEAN LAMONTE EVANS; Fiscal Year: 2012
    ..Understanding the interactions between these two molecules will help improve the strategy for finding inhibitors that can block this interaction, thus providing a potential for novel anti-HIV drugs. ..
  51. Inhibitors Targeting HIV Integrase Multimers
    Jacques J Kessl; Fiscal Year: 2012
    ..Aim 1 will focus to increase the binding specificity and affinity of compound 1 for the "bottom" pocket;aim 2 will rationally design new allosteric molecules selectively binding the "side" pocket. ..
  52. Peptide Inhibitors of HIV-1 Vif Function
    John Donahue; Fiscal Year: 2007
    ..This research is relevant to public health because it may lead to the development of new therapeutic agents for the treatment of HIV/AIDS. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  53. Carcinogenicity Testing of Novel Phenanthrene Diketoacid Anti-HIV Agents
    John Buolamwini; Fiscal Year: 2009
    ..The results of the research will determine whether to carry on with further work on optimizing this class of new anti-HIV agents towards AIDS therapeutics development. ..
  54. Synthesis of New NNRTLs for the Treatment of AIDS
    Mark Cushman; Fiscal Year: 2005
    ..The activities of the ADAMs vs. NNRTI resistant viruses will be investigated. The aqueous solubilities of the new ADAMs will be measured accurately. ..
  55. SYNTHESIS ANTI-HIV AGENTS THAT TARGET ZINC FINGERS
    MARK WELKER; Fiscal Year: 2000
    ..Isolable thiolate conjugates would also be subjected to the battery for screens described in Specific Aim 1. ..
  56. PLANT ANTI-HIV AGENTS
    Kuo Hsiung Lee; Fiscal Year: 2013
    ..abstract_text> ..
  57. NOVEL APPROACHES TO THE DISCOVERY OF ANTI-HIV AGENTS
    Yitzhak Tor; Fiscal Year: 2007
    ..Potent and specific effectors of essential regulatory events will significantly advance the development of highly active antiretroviral agents. ..
  58. FLP-102: Rationally Engineered Antiviral Protein
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
  59. MECHANISMS OF SELECTIVE ACTIONS OF ANTIVIRAL AGENTS
    Ram Agarwal; Fiscal Year: 2003
    ..HIV sensitivity to 3TC, ddC, and AZT in the resistant cells will be examined by p24 analysis. Understanding of these factors will help design strategies to improve effectiveness of the antiviral agents. ..
  60. ORAL BIOAVAILABILITY AND VARIABILITY OF ANTIAIDS DRUGS
    Patrick Sinko; Fiscal Year: 2000
    ....
  61. Intravaginal ring microbicide formulations comprising multiple anti-HIV agents
    Thomas Smith; Fiscal Year: 2009
    ..We propose to utilize this platform technology to develop long-term vaginal ring formulations for the potential microbicides tenofovir and TMC-120. ..
  62. Statistical Methods for Complex HIV Cohort Studies
    Peter Bacchetti; Fiscal Year: 2004
    ..Applications to relevant data sets will provide both realistic testing and new substantive insights. Software implementing the methods and technical papers will be available through the Internet at a project-related website. ..
  63. Synthesis/Biological evaluation of Anti-HIV Nucleosides
    David Chu; Fiscal Year: 2005
    ..This is the first such studies demonstrating the potential of this molecular modeling approach. ..
  64. Chemokine receptor CCR5 antagonists as novel anti-HIV agents
    Yan Zhang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..